EyePoint Pharmaceuticals (EYPT) Stock Plummets 71% Following Phase 3 Trial Disappointment

EyePoint Pharmaceuticals (EYPT) stock crashed 71% after DURAVYU missed its primary Phase 3 endpoint, though secondary results showed promise.

The post EyePoint Pharmaceuticals (EYPT) Stock Plummets 71% Following Phase 3 Trial Disappointment appeared first on Blockonomi.